07:00 , Jul 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Not applicable...
07:00 , May 4, 2009 |  BC Week In Review  |  Clinical News

Avodart: Post-marketing study data

In an open-label study of 212 patients, switching from branded alpha blockers or 5-alpha reductase inhibitors to generics resulted in significant diminution in efficacy and an increase in adverse events after 8 weeks. In the...
08:00 , Jan 10, 2005 |  BC Week In Review  |  Company News

Andrx drug delivery, generics news

ADRX will exit its branded pharmaceuticals business to focus on generics and distribution. Banc of America Securities LLC will solicit offers for the branded business, which had an operating loss of $31 million for the...
07:00 , Sep 27, 2004 |  BioCentury  |  Product Development

More benign for BPH

Marketed treatments for benign prostatic hyperplasia (BPH) have side effects such as hypotension or sexual dysfunction. BioXell S.p.A. says that its BXL-628 vitamin D3 analog is the first compound to reduce prostatic volume in clinical...
07:00 , Jun 28, 2004 |  BC Week In Review  |  Clinical News

Cardura doxazosin regulatory update

PFE received an FDA approvable letter for Cardura XL. The compound is a sustained-release formulation of doxazosin, which PFE markets to treat benign prostatic hyperplasia (BPH). Under a 2003 deal, ADRX will have exclusive U.S....
08:00 , Dec 8, 2003 |  BC Week In Review  |  Company News

Andrx, Pfizer sales and marketing update

ADRX will become the exclusive U.S. distributor of PFE's Cardura XL doxazosin. Cardura XL is a sustained-release formulation of the alpha adrenergic receptor subtype selective inhibitor, which is marketed to treat benign prostatic hyperplasia...
08:00 , Mar 20, 2000 |  BC Week In Review  |  Clinical News

(S)-doxazosin: Began Phase I testing

Sepracor Inc. (SEPR), Marlborough, Mass.   Product: (S)-doxazosin   Business: Urological   Therapeutic category: Receptor antagonist   Target: Alpha adrenergic receptors   Description: Single isomer form of Pfizer Inc.'s Cardura alpha adrenergic receptor subtype selective inhibitor   Indication:...
08:00 , Jan 20, 1997 |  BioCentury  |  Regulation

Racemic pipeline

Racemic pipeline R-Albuterol Sepracor Asthma/COPD Phase III R-Ketoprofen Sepracor Pain Phase II S-Ketoprofen Sepracor Periodontitis Phase II S-Fluoxetine Sepracor Migraine Phase II S-Oxybutynin Sepracor Incontinence Phase II D-Methyl phenidate Celgene Attn deficit IND/Phase I D-Methyl...
07:00 , Aug 5, 1996 |  BC Week In Review  |  Clinical News

Sepracor regulatory update

SEPR received three U.S. patents covering its Improved Chemical Entities (ICEs). Patent No. 5,532,278 covers the use of purified versions of S-oxybutynin, which is in Phase I/II trials to treat urinary incontinence. Patent No. 5,510,352...
07:00 , Jun 7, 1993 |  BioCentury  |  Strategy

Sepracor's R& D pipeline

Sepracor's R& D pipeline Generic name Brand name Company Patent expires Indication Sepracor status atenolol Tenormin ICI/Zeneca Exp. Hypertension Pre-Reg in Europe Approved In Denmark ketoprofen Orudis Rhone-Poulenc Rorer Exp. Periodontal disease Phase II 3Q93...